dc.contributor.author |
Mahmuda, A |
|
dc.contributor.author |
Bande, F |
|
dc.contributor.author |
Al-Zihiry, K.J.K |
|
dc.contributor.author |
Abdu Majid, R |
|
dc.contributor.author |
Hamat, R. A |
|
dc.contributor.author |
Abdulhaleem, N |
|
dc.contributor.author |
Abdullah, W. O |
|
dc.contributor.author |
Unyah, Z |
|
dc.date.accessioned |
2017-11-10T15:03:20Z |
|
dc.date.available |
2017-11-10T15:03:20Z |
|
dc.date.issued |
2017-02-17 |
|
dc.identifier.issn |
1596-5996 |
|
dc.identifier.uri |
http://hdl.handle.net/123456789/600 |
|
dc.description.abstract |
The increasing demand for monoclonal antibodies (mAbs) used for diagnostic and therapeutic
applications has led to the development of large scale manufacturing processes, with improvements in
production achieved through continuous optimization of the inherent systems. The number of
monoclonal antibodies (mAbs) that have already been approved for therapeutic applications and for use
in clinical trials have significantly increased in the past few years. In view of the side effects and
limitations of mAbs, several improvements and modifications to monoclonal antibodies have been
developed. These modifications have facilitated the use of mAbs in various forms of therapeutic
applications such as treatment of infectious diseases caused by bacterial, viral, fungal and parasitic
organisms. Monoclonal antibodies have also been applied in the treatment of non-infectious diseases
such as cancer, immune diseases, arthritis and other disorders resulting from organ transplantation.
This review highlights mAbs applications in biomedicine, and discusses state-of-the-art technologies
related to their potential uses. |
en_US |
dc.language.iso |
en |
en_US |
dc.publisher |
Pharmacotherapy Group, Faculty of Pharmacy, University of Benin |
en_US |
dc.subject |
Department of Parasitology and Entomology |
en_US |
dc.title |
Monoclonal antibodies: A review of therapeutic applications and future prospects |
en_US |
dc.type |
Article |
en_US |